Podcasts about Cancer research

This is episode three of Swimming with Shadows: A Radiolab Week of Sharks.Today, we take a trip across the world, from the south coast of Australia to … Wisconsin. Here, scientists are scouring shark blood to find one of nature's hidden keys, a molecular superhero that might unlock our ability to cure cancer: shark antibodies. They're small. They're flexible. And they can fit into nooks and crannies on tumors that our antibodies can't.We journey back 500 million years to the moment sharks got these special powers and head to the underground labs transforming these monsters into healers. Can these animals we fear so much actually save us? Special thanks to Mike Criscitiello, David Schatz, Mary Rose Madden, Ryan Ogilvie, Margot Wohl, Sofi LaLonde, and Isabelle Bérubé.EPISODE CREDITS: Reported by - Becca BresslerProduced by - Becca Bressler and Matt KieltyOriginal music from - Matt Kielty and Jeremy BloomSound design contributed by - Matt Kielty, Jeremy Bloom, and Becca Bresslerwith mixing help from - Jeremy BloomFact-checking by - Diane Kellyand Edited by  - Pat WaltersSignup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

Join me in the latest Dog Gone Positive Way episode as I interview Cindy, who started Scout and Zoe's Unique Treats, Food, and Chews. In this episode, we delve into International business trade. The Middle East and Asia are just a few international areas that will be introduced to Scout and Zoe's Unique Treats, Chews, and Food. Cindy also started a 501(c)(3) SCOUTING FOR A CURE, to raise funds for cancer research in dogs and cats. You can also donate to memorialize your pet and your funds will go towards Cancer Research. A disease I know many of us have experienced, saying goodbye to our pets when they pass away from cancer and go to the Rainbow Bridge.Cindy is tackling the invasive species of fish known as Carp. Cindy's love of dogs and all pets fuels this unique company's passion. From Carp Bubblers, kangaroo jerky, trout heads, duck heads, tendons, and everything in between, you will find amazing treats and food, and chews that will keep your pets happy, healthy, busy, and nourished.10% off CODE: Bubblers GO TO scoutandzoes.com You can find Cindy on social media @scoutandzoes#InternationalTrade #cancer #dog #puppy #cat #kitten #podcast #treats #rainbowbridge #dogmom #cancerresearch

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textSend me feedback hereDr. Bobby begins with a walk through his local deli, which sparked a deeper investigation into what actually goes into processed meats. He outlines how processed meats are defined by the USDA as those altered through salting, curing, or smoking for preservation, dating back to Paleolithic food practices. The real concern, he explains, lies in compounds like nitrates (NO3) and nitrites (NO2), which can convert into nitrosamines, a group of chemicals potentially linked to colorectal cancer.Citing the American Institute for Cancer Research and the International Agency for Research on Cancer, Dr. Bobby notes that processed meats have been labeled carcinogenic, with consumption linked to an increased cancer risk. However, he contrasts this with a weak recommendation from the Nutritional Recommendations Consortium, which found low-certainty evidence that processed meat increases cancer risk, suggesting most people could continue their usual consumption patterns.He scrutinizes observational studies like the UK Biobank study and a meta-analysis of 15 studies involving 2.5 million participants, both hinting at a modest increased risk but fraught with methodological flaws such as poor adjustment for confounders like diet, exercise, and lifestyle habits.The conversation deepens with the Shanghai study that found nitrate-related cancer risk only in individuals with low vitamin C intake, pointing to the potentially protective effects of antioxidants. Supporting this, Dr. Bobby highlights that 70% of dietary nitrates come from vegetables like spinach and beets, which are associated with lower cancer risk, adding nuance to the nitrate debate.And it gets more paradoxical—beetroot juice rich in nitrates has been shown in 75 randomized controlled trials to lower blood pressure by up to 7 points systolic, rivaling medication.To put things into perspective, Dr. Bobby crunches the numbers: if processed meats raise colorectal cancer risk by 13%, your lifetime risk might increase from 4% to 4.4%—a marginal difference. In real terms, out of 1,000 people who completely avoid processed meats, only four might avoid colorectal cancer.Other additives like sodium erythorbate and sodium ascorbate appear non-problematic at normal levels, and while sodium may raise blood pressure in salt-sensitive individuals, it's not linked to cancer risk—explored further in Episode 27.Dr. Bobby closes with a pragmatic and humor-tinged "bacon hack": since vitamin C may counteract the formation of harmful nitrosamines, consider enjoying your bacon with a glass of orange juice—a personal theory grounded in biochemical plausibility but not tested.Takeaways: If you enjoy processed meats, the absolute cancer risk appears minimal based on current evidence. Leafy vegetables, despite their high nitrate content, are protective—likely due to vitamin C and other antioxidants. To balance pleasure and prudence, pair your bacon with a side of vitamin C, and above all, remember: wellne

In this week's Talking Health, Jessica is joined by Dr Juho Jalkanen to discuss a new blood cancer trial which has shown highly promising results, particularly for patients who have relapsed or live with hard-to-treat forms of the disease.

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's a controversial topic - but with communal discipline still common in many cultures, does it truly take a village to raise a child? And if so, how do you establish the norms in your own community. Helen puts it to three parenting experts. Meanwhile, as a major oncology conference in the USA hears how cancer patients are now delaying or refusing treatment in favour of miracle diets, essential oils and advice from TikTok influencers with no medical qualifications, Helen factchecks some medical claims with breast cancer surgeon turned patient, Dr Liz O'Riordan. We get the facts on healthcare before travel, and vaccine catch-ups, with Dr Howard Podolsky, and Tom Poulson from Haus&Haus is also on hand to talk property buying mistakes, and how to avoid them. See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: FDA approves new drug for treatment of rare genetic diseaseIn a significant development for the rare disease community, the FDA has approved a new drug for the treatment of a rare genetic disease. The drug, which is the first of its kind, has shown promising results in clinical trials and is expected to provide much-needed relief for patients suffering from this condition.##News 2: Biotech company announces breakthrough in cancer researchA leading biotech company has announced a major breakthrough in cancer research. The company's new treatment has shown significant efficacy in treating a variety of cancers, offering hope to patients who previously had limited treatment options. This development marks a significant step forward in the fight against cancer.##News 3: Pharma company reports positive results in COVID-19 vaccine trialsA pharmaceutical company has reported positive results in clinical trials for its COVID-19 vaccine candidate. The vaccine has shown high efficacy rates in preventing infection and reducing the severity of symptoms in vaccinated individuals. This news comes as a welcome development in the ongoing battle against the global pandemic.##News 4: Biotech startup secures funding for innovative gene therapyA promising biotech startup has secured funding for its innovative gene therapy approach. The therapy, which targets a range of genetic disorders, has shown promising results in preclinical studies and is now moving towards clinical trials. This funding will help accelerate the development of the therapy and bring it one step closer to market availability.##News 5: Pharma giant announces collaboration with leading research institutionA major pharmaceutical company has announced a collaboration with a leading research institution to advance drug discovery efforts. The partnership aims to leverage the expertise of both organizations to accelerate the development of new treatments for a variety of diseases. This collaboration represents a significant step forward in the quest for innovative therapies.##News 6: Biotech conference showcases latest advancements in gene editing technologyA recent biotech conference showcased the latest advancements in gene editing technology. Researchers presented cutting-edge techniques that have the potential to revolutionize the field of genetic engineering. These advancements hold promise for developing new treatments for a wide range of diseases and disorders.##That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest developments in the world of pharmaceuticals and biotechnology. Thank you for listening!

Three of our favorite segments from the week, in case you missed them.Katie Barnes, award-winning LGBTQ sports journalist, on trans women and girls in sport (First) | A recap of the first NYC mayoral debate (Starts at 47:30) | A 100-year history of Cancer research in the United States (Starts at 1:25:10)If you don't subscribe to the Brian Lehrer Show on iTunes, you can do that here.

We speak with Dr. Georgia Konstantinidou and Dr. Chiara Pozzato from University of Bern about their recent pre-clinical research investigating a new potential treatment approach for KRAS driven cancers. The conversation explores the role of FAK signalling in KRAS driven NSCLC and potential approaches to bypass drug resistance against FAK inhibitors from the molecular mechanisms involved to the impact of their study for the wider cancer research community. This study has been published in EMBO Molecular Medicine and was included in the EACR's Highlights in Cancer Research, a summary of the most interesting and impactful recent papers in cancer research.

Expanding access to clinical trials in community oncology settings is essential to improving diversity, equity, and inclusion in cancer research. In this episode, CANCER BUZZ speaks with clinical research coordinator, Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP, whose cancer center recently participated in a foundational oncology clinical trials course, developed by ACCC and the Association of Clinical Research Professionals (ACRP) to help cancer programs expand availability of trials to traditionally underserved communities. Oladipupo shares how this training prepared their center for the challenges of a growing research program, the progress they've made, and the pivotal role of clinical research coordinators in expanding research programs and improving patient access to clinical trials.   Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP Clinical Research Coordinator Touro-Cancer Center New Orleans, LA   “We know that diversity is a big point, not only as per new FDA guidance, but [to] ensure that every participant is given an equal opportunity to hear about the study. [Our] approach is not to target a certain group of individuals. Really the approach is to target any individual that looks potentially eligible.” - Oluwakemi “Kemi” Oladipupo   Resources:  Community Oncology Can Close the Gap in Cancer Research Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator The Role of the Clinical Trials Navigator — [MINI PODCAST] EP 129 Human-Centered Design: A Possible Solution to Rural Clinical Trial Enrollment

You can go to my sponsor https://aura.com/sagesteele to try 14 days for free. That's enough time for Aura to start scrubbing your personal info off these data broker sites, without you lifting a finger. Kirk Cameron joined me for a conversation that hit deeper than I expected. If you're thinking of the teen idol from Growing Pains, sure, that's part of his story. But today, Kirk's a husband, a dad of six (four adopted), a new grandfather, and someone who's been unafraid to speak out about his faith and values. This wasn't just a conversation—it was a reminder that purpose, connection, and peace of mind are choices. Kirk doesn't preach; he shares. And that's why this episode matters. Chapters: 03:39 – Backyard chickens, socks, and moving to Tennessee 06:01 – Duck hunting memories and Phil's legacy 11:41 – Baptism story and spiritual transformation 15:01 – Peace of mind, daily faith practice, and handling loss 21:31 – How Kirk found Christianity at 17 during Growing Pains 26:01 – Kirk's faith unintentionally brings his whole family to church 32:21 – Faith, courage, and what we choose to worship 36:01 – Falling in love with Chelsea and becoming “Chief” 39:01 – Marriage longevity and the power of forgiveness 43:01 – Why marriage is delayed in today's culture 47:01 – Raising kids with faith and purpose 51:01 – Parenting adult kids and grandparenting joy 56:01 – The adoption story: four kids before two biological 01:00:01 – Multiracial family dynamics and identity About Kirk: Kirk Cameron is a lifelong actor, husband, father of six, and committed Christian. Best known as “Mike Seaver” on the hit '80s sitcom Growing Pains, Kirk went on to star in Fireproof, Left Behind, and Lifemark, and produced the documentaries Monumental and The Homeschool Awakening. With his wife Chelsea, he co-founded Camp Firefly, a free summer camp for families of terminally ill children. He also hosts Takeaways with Kirk Cameron and One on One with Kirk Cameron on TBN, and continues to speak out through his American Campfire Revival tour and podcast. Kirk recently authored the children's book As You Grow, encouraging Biblical values and character for the next generation. About Sage: Sage Steele is a longtime national TV broadcaster and current host of The Sage Steele Show on YouTube and all podcast platforms. From 2007 to 2023, she was a mainstay at ESPN, anchoring SportsCenter and leading coverage of major events like the Super Bowl, The Masters, NBA Finals, and the World Series. She also hosted NBA Countdown on ESPN and ABC from 2013–2017. Outside of sports, Sage has hosted national broadcasts including the Miss America Pageant, Scripps National Spelling Bee, the Rose Parade, and ABC's Volcano Live with Nik Wallenda. She's appeared on The View, Jimmy Kimmel Live, and has been featured in Rolling Stone, Variety, and The Wall Street Journal.A graduate of Indiana University, Sage began her journalism career in local news before rising to regional and national prominence. She now serves on the boards of the Boys & Girls Clubs of America and The V Foundation for Cancer Research.She's a proud mom of three and currently resides in Florida. Subscribe to the Channel for more Podcasts like this! Listen to the Show on all Podcast Apps "The Sage Steele Show" https://podcasts.apple.com/us/podcast/the-sage-steele-show/id1737682826 Follow Sage: https://www.sagesteele.com https://x.com/sagesteele https://www.instagram.com/sagesteele https://www.tiktok.com/@officialsagesteele https://rumble.com/c/SageSteeleProductions Follow Kirk: @kirkcameronofficial @bravebooks.us braveplus.com (http://braveplus.com/) Learn more about your ad choices. Visit megaphone.fm/adchoices

- Understanding the Future of Cancer Research & Clinical Trials - Increased Focus on Earlier Detection & Treatment of Cancer - Health Care Disparities Research - Enhanced Knowledge of the Molecular Portrait of Cancer - Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer - Microsatellite Instability (MSI): Mutations in DNA Mismatch Repair Genes – Implications for Treatment - Immunotherapy - CAR T-Cell Therapy - Immune Checkpoint Inhibitors & Blockade - Monoclonal Antibodies - Cancer Treatment Vaccines - Immune System Modulators - Targeted Immunotherapies - Radiopharmaceutical Therapy (RPT) - Antibody-Drug Conjugates (ADCs) - Robotic Surgery - Additional Focus on Lifestyle, Exercise, Nutrition & Hydration - Increasing Role of Telehealth/Telemedicine Appointments - Questions for Our Panel of Experts

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Emil Lou, Professor of Hematology and Oncology at the University of Minnesota. They discuss the promising results of a recent clinical trial he led focused on gastrointestinal cancers, the potential impact of continued clinical success on the future of these hard-to-treat cancers, and the key challenges that must be addressed to sustain progress. Dr Lou also explores the evolving role of multiplexed gene editing in tackling immunosuppressive or heterogeneous solid tumours, the complexities of forging academia-industry partnerships to support early-phase innovation, and the scientific breakthroughs he believes will shape the next five years in cancer research. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The New York Times reports that "President Trump proposed chopping funding at the National Cancer Institute by more than $2.7 billion, nearly a 40 percent decrease." It's part of a significant cut to the National Institutes of Health. Our guests work in cancer research and treatment. They discuss the possible impact of this news, as well as the state of cancer care. In studio: Jonathan Friedberg, M.D., MMSc, director of Wilmot Cancer Institute  Charles Kamen, Ph.D., MPH, associate director for community outreach and engagement at  Wilmot Cancer Institute and associate professor in the Departments of Surgery and Psychiatry at the University of Rochester Medical Center Emily Hayes, MPA, program manager for community outreach and engagement at Wilmot Cancer Institute

This year's WNYC Health Convening with support from the Alfred P. Sloan Foundation continues with a look at the current state of cancer research in the United States. Sudip Parikh, Ph.D., chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals, and Otis Brawley, professor of oncology at The Kimmel Cancer Center at Johns Hopkins, a Bloomberg Distinguished Professor at Johns Hopkin and co-editor of The Cancer History Project, and Julie Rovner, chief Washington correspondent at KFF Health News and host of the What the Health? podcast, discuss what the impacts of the Trump administration's funding cuts to the National Health Institute have meant to clinical trials, and what a future without government funding to find a cure might look like should the science continue to be underfunded.

Each year the news division hosts the WNYC Health Convening with support from the Alfred P. Sloan Foundation as an opportunity for healthcare experts and practitioners to inform WNYC's health reporting. This year, as part of our centennial series "100 Years of 100 Things," Paul Goldberg, editor and publisher of The Cancer Letter and co-editor of The Cancer History Project, discusses the century of cancer treatment advancements and how the U.S. government played a major part in funding the science for treatment, early detection and prevention.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Artificial intelligence is reshaping our world – but what does that mean for healthcare, scientific discovery, and human potential? In Genesis: Artificial Intelligence, Hope, and the Human Spirit, co-authors Craig Mundie, Henry Kissinger, and Eric Schmidt explore the profound implications of AI on society. In this collaborative event between Town Hall Seattle and the Institute for Systems Biology (ISB), Craig Mundie joins Dr. Jim Heath, President of ISB, for a thought-provoking conversation about the future of AI. They will discuss insights from the book, the opportunities and challenges AI presents, and what it means for the way we live, work, and care for our health. Co-author, Genesis: Artificial Intelligence, Hope, and the Human Spirit, Craig Mundie is a leading technology executive and former Chief Research and Strategy Officer at Microsoft. Over his decades-long career, he has played a pivotal role in advancing artificial intelligence, computing, and national security initiatives. Alongside Henry Kissinger and Eric Schmidt, he co-authored Genesis, a deep exploration of AI's impact on society and the future of humanity. Mundie has served as an advisor to the U.S. government on technology policy and was a member of the President's Council of Advisors on Science and Technology. President and Professor, Institute for Systems Biology (ISB) Dr. Jim Heath is a pioneering scientist in systems biology, cancer research, and precision medicine. Since 2018, he has led ISB, driving interdisciplinary research in cancer and immune system dynamics while advancing innovative approaches to complex diseases. An internationally recognized scientist, Heath has received numerous honors, including the Irving Weinstein Award from the American Association for Cancer Research and the Sackler Prize in the Physical Sciences. Before ISB, he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech and a Professor of Molecular and Medical Pharmacology at UCLA. Presented by Town Hall Seattle and Institute for Systems Biology. Buy the Book Genesis: Artificial Intelligence, Hope, and the Human Spirit Elliott Bay Book Company

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Losing her job, her security, and even her teeth weren't enough to silence Sage Steele, host of The Sage Steele Show and former ESPN sportscaster. On this special episode of The Narrative, Sage candidly shares why she left ESPN as well as her testimony of courage, conviction, and the sustaining power of prayer at our Cincinnati Celebration Gala. Before Sage takes the stage, CCV President Aaron Baer and Communications Director Mike Andrews sit down to discuss the school choice wins in the One, Big, Beautiful Bill. They also discuss a movement by statewide pastors and ministry leaders to oppose Senate Bill 197, Ohio's gambling expansion bill, and how this bill would impact the most vulnerable. More about Sage Steele Sage Steele is one of the country's most popular and respected broadcasters of her generation. She currently hosts The Sage Steele Show, a weekly podcast, where she sits down with entertainers, athletes, business people, and politicians to have deep dive personal one-on-one discussions that enlighten, entertain, and engage. Prior to launching her show, she was a leading fixture at ESPN from 2007-2023, hosting the network’s flagship show, SportsCenter. Through the years, Sage has been a featured guest host on ABC's The View, was a guest on Jimmy Kimmel Live, and has been profiled by numerous publications, including Rolling Stone, Variety, The Wall Street Journal, Vibe, and Huffington Post. Sage is proud to be a new member of the board of directors for The Boys & Girls Club of America. She is also in her third year as a board member for The V Foundation for Cancer Research, an advisory board member for the Multiple Myeloma Research Foundation (MMRF) and volunteers with The Alzheimer’s Association. Most importantly, Sage is the proud mother of three children, and she resides in Florida.

Gerry Allan is a cancer survivor, and he's doing a 200km cycling challenge in Toronto next weekend. Him and his son Michael, who does it with him, joined us this morning to discuss.

It's a big day at WCCO, not just Chad's birthday but its the Cure Blood Cancer Radio Auction in partnership with NMDP! Chad is joined by Todd Peterson who is the Executive Director with NMDP. Chad and Todd talk about what brought him to working with NMDP and the interactions they have with people when they reach out to the organization after being touched by blood cancer.. They take bids on the Twins Executive Balcony package where 20 ticket winners join Chad Hartman, Dave Harrigan for the Thursday, June 26th 12:10p game vs Seattle Mariners. The experience includes fully catered food & beverage from one of the coolest private viewing spots at Target Field! In the second half of the hour Chad and Dave take bids on the TPC/3M Package which includes golf/tee times for 4 at the exclusive TPC club in Blaine...PLUS, 4 tickets to the 3rd round at the 3M Open, on Saturday July 26th - which includes a concert that evening with country music recording & touring artist Lee Brice.

Join Dr. Kristi Funk as she debunks the myth about protein intake and reveals top plant-based sources. Learn why you don't need to worry about protein deficiency and discover the power of soy, lentils, beans, and more. Transform your diet with these delicious and nutritious options! #PlantBasedProtein #HealthyEating #BreastCancerPrevention

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A patient death has led to the halt of Rocket's gene therapy trial for Danon disease, due to complications from an acute systemic infection. This incident highlights the unpredictable nature of gene therapies and may pose challenges for investment in the field. On the other hand, mRNA technology has been both helped and hindered by the COVID-19 pandemic. While the pandemic has increased interest and funding in mRNA research, vocal skeptics of COVID-19 vaccinations have negatively impacted the reputation of mRNA technology. Despite this, some see promise in mRNA for therapeutics in cancer and rare diseases.In other news, Prothena is considering business options after a failed phase III trial, and a new biotech company has been launched to focus on neuro diseases. Additionally, AGC Biologics will be at Bio International to showcase their capabilities in protein biologics and advanced therapies.mRNA technology played a significant role in combating COVID-19, but is now facing scrutiny due to vaccine skeptics and cuts in government funding for research. Despite this, the pandemic accelerated advancements in mRNA therapeutics for cancer and rare diseases. The lack of FDA-approved treatments for rare diseases, particularly in children, highlights a critical need for innovation in this area. The American Association for Cancer Research's annual conference will unveil data that could impact cancer treatment, while the future of vaccine development faces challenges amidst regulatory changes and funding issues. Additionally, advancements in cell and gene therapy are on the horizon. Suggestions for coverage topics in the biopharma industry are welcomed.

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On the next Charlotte Talks, we look at the treatment, screening and testing options for prostate cancer patients. We also look at promising new treatment research recently released by Duke University and hear from a prostate cancer survivor.

Philippa Charles, Director of the DFN Charitable Foundation, leads a conversation on the Foundation's strategic philanthropic approach and its distinctive commitment to long-term, systems-level impact. With a background in leading one of the UK's major family foundations and now at the helm of DFN, she offers a compelling look at how deeply personal motivations can shape focused and effective grantmaking. The DFN Foundation operates across four thematic pillars: disability education, disability employment, myeloma cancer research, and conservation. These areas are not only strategic but are also rooted in the lived experiences and values of the Foundation's founding family. This grounding translates into a uniquely empathetic and effective model of philanthropy—one that combines substantial funding with strategic oversight and deep engagement with delivery partners. The episode explores how DFN supports systemic change in disability inclusion. Philippa discusses the success of Undershaw, a school for students with special educational needs that recently received an “Outstanding” rating from Ofsted, and the DFN Project SEARCH initiative, which has helped more than 3,000 young people with disabilities secure meaningful employment across over 200 corporate and public sector partners. These stories illustrate DFN's commitment not just to education and training but to shifting the broader landscape of opportunity for disabled individuals. A similarly strategic approach underpins the Foundation's investment in myeloma research. Through the Jacquelin Forbes Nixon Fellowship, DFN has supported a clinical trial at the Institute of Cancer Research that is producing transformative outcomes. Over 75% of participants remain in remission—a significant improvement over standard care—and the research now points toward wider clinical application and deeper exploration into treatment efficacy and patient outcomes. DFN's work extends beyond the UK, particularly in conservation. In Kenya, the Foundation supports the Pangolin Project, an initiative preserving 5,000 hectares of biodiverse forest and protecting the world's most trafficked and critically endangered mammal. The project embodies the Foundation's ability to balance localized impact with global relevance, and its philosophy of acting where there is both clear need and the opportunity for catalytic intervention. Throughout the discussion, Philippa reflects on the leadership demands of running a multifaceted family foundation. She shares how she is structuring her first year in the role by focusing on governance, partnerships, operational strategy, and long-term vision. Her insights offer a valuable roadmap for those leading or advising mission-driven organizations, especially those navigating the complexities of family philanthropy. The conversation concludes with a discussion of collaboration across the sector and the importance of peer networks among foundations. Philippa also speaks passionately about the transformative power of volunteering, not only as a form of civic engagement but as a professional and personal development tool. For those interested in strategic philanthropy, disability inclusion, evidence-based research funding, and conservation efforts with measurable impact, this episode provides a thoughtful and informative exploration of how one foundation is driving change across sectors—anchored in personal values, executed with professional discipline, and amplified through strategic partnerships. Thank you for downloading this episode of the Do One Better Podcast. Visit our Knowledge Hub at Lidji.org for information on 300 case studies and interviews with remarkable leaders in philanthropy, sustainability and social entrepreneurship.  

In this episode of the DAV Podcast, host Brian Buckwalter speaks with Dr. Ben Park, Director of the Vanderbilt Ingram Cancer Center, about the critical state of cancer research and its direct impact on military veterans. Dr. Park highlights the groundbreaking progress in cancer treatment, including innovative cellular therapies performed at the Nashville VA Hospital, and expresses grave concerns over recent, unprecedented funding cuts. He emphasizes that these cuts not only jeopardize patient lives and the continuation of life-saving research but also hinder the training of future medical professionals, ultimately undermining the commitment to provide veterans with the best possible care they deserve.

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

A report from Senator Bernie Sanders found that Trump officials cut $2.7B in NIH funding in the first three months of 2025, including a 31 percent cut to cancer research.

This episode teaches that innovation is born at the intersection of curiosity and persistence. Dr. Gudrun Stengel, co-founder and CEO of Alida Biosciences, reveals how her startup is transforming the landscape of RNA research through a novel technology called proximity barcoding. Dr. Stengel's story exemplifies the power of entrepreneurial spirit in driving scientific discovery, offering a glimpse into how one idea can reshape an entire field.At Alida Biosciences, Dr. Stengel and her team are pioneering new tools for detecting RNA modifications, a largely unexplored realm of epigenetics. Using their proximity barcoding platform, researchers can read multiple RNA modifications simultaneously, uncovering potential biomarkers and therapeutic targets for diseases like cancer, Alzheimer's, and diabetes. This technology bridges a critical gap in multiomics, allowing scientists to dive deeper into how epigenetic changes influence gene expression and cellular behavior.Beyond the lab, Dr. Stengel shares her experience as a first-time founder, balancing scientific rigor with startup life. From managing a team to fundraising, her journey underscores the importance of resilience, optimism, and maintaining a long-term vision. She also offers valuable advice for budding scientists, encouraging them to embrace challenges and remain persistent in the face of setbacks. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

The National Institutes of Health is the largest public funder of biomedical research in the world, but under the Trump administration, NIH is freezing funding to several universities, including Northwestern. One of the projects being delayed is cutting-edge research on ovarian and pancreatic cancer. Reset learns more about the effect of this freeze on patients and early career scientists with Josh Leonard, professor of chemical and biological engineering at Northwestern University. For a full archive of Reset interviews, head over to wbez.org/reset.

Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms related to hormone excess, including carcinoid syndrome and carcinoid heart disease, managing symptoms of functioning pancreatic neuroendocrine tumors, and also palliative interventions. Dr. Perez and Del Rivero share how to use this guideline in concert with the systemic therapy for tumor control in metastatic well-differentiated GEP-NETs guideline, and hope for the future for the treatment of gastroenteropancreatic neuroendocrine tumors. Read the full guideline, “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Transcript This guideline, clinical tools, and resources are available on ASCO.org. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in JCO Oncology Practice.        Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Kim Perez from Dana-Farber Cancer Institute and Dr. Jaydira Del Rivero from the Center for Cancer Research at the National Cancer Institute, co-chairs on “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Thank you for being here today, Dr. Del Rivero and Dr. Perez. Dr. Kim Perez: Thank you. Dr. Jaydira Del Rivero: Thank you so much for the invitation. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Perez and Dr. Del Rivero, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to jump into the content here, first Dr. Del Rivero, could you provide an overview of the scope and purpose of this guideline? Dr. Jaydira Del Rivero: Yeah. Thank you so much. Well, first, we really wanted to thank ASCO for allowing us to develop these guidelines for the management of gastroenteropancreatic neuroendocrine tumors. I do want to mention that there is also another set of guidelines that I was very fortunate also to co-chair with Dr. Perez on the systemic management of gastroenteropancreatic neuroendocrine tumors. But when discussing these guidelines as well as with the different panelists, experts in this type of disease, we also realized that the management of these tumors are quite complex, not only from the management of the disease progression, but at the same time, management of the symptoms related to the hormone excess. And because of that, we like to thank ASCO for allowing us to then not only have a discussion on the systemic management of these tumors, but at the same time develop recommendations for the symptoms related to the different hormones that these neuroendocrine tumors may produce. These guidelines are for the management of grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. These guidelines include the management of the different aspects and the symptoms related to hormone excess, such as carcinoid syndrome, carcinoid heart disease, how to manage carcinoid crisis, as well as the different symptoms and how to manage the functional pancreatic neuroendocrine tumors and as well as provide recommendations in the different treatments for these tumor types, not only from the systemic management but also from the surgical management as well as for liver-directed therapy options and the different aspects in terms of the palliative care of these patients to improve not only the symptoms related to the hormone excess caused by these tumors, but as well as to improve the quality of life. Brittany Harvey: Absolutely. And I appreciate that overview. And yes, we'll link the guideline on the Systemic Therapy for Tumor Control for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors in the show notes for our listeners so that they can refer to that companion guideline as well. So then you just described the several different categories of recommendations that this guideline covers on symptom management. So, Dr. Perez, I'd like to start reviewing some of those key recommendations of that guideline. So, starting with what are the key recommendations for carcinoid syndrome and carcinoid heart disease? Dr. Kim Perez: Thank you Brittany. Yeah, I also want to thank ASCO for inviting us to do this podcast today. Just to start, I think these guidelines will really add to what's available in the literature to provide a kind of a quick look for the community provider to manage carcinoid-related symptoms. I think the highlights that I would point out are we've all been using somatostatin analogs for the last few decades to manage symptoms, but with the newer treatments that are now available, we tried to highlight what does the literature support in regards to PRRT, what does the literature support in regards to using systemic therapy for disease management, but also the benefits that you will get from a symptom management perspective using other modalities. I think the highlight really is it's a multidisciplinary approach. We are now considering surgery and embolization or interventional radiology as a critical piece. And I think the third that I'd highlight is the fact that sometimes we get too focused on carcinoid syndrome and the symptoms will actually, may result from other things. And the highlight in the algorithms that we've provided is what other things cause carcinoid-related diarrhea. And let's not forget about that because we will find ourselves treating and patients getting very frustrated with persistence of symptoms when in actuality, we should be treating something else that is causing a very similar symptom. For carcinoid heart disease, I think there are more and more guidelines that are now available to provide guidance there, but I think the major advances are that we should be utilizing heart assessment with echocardiogram with lab values such as BMP. But also critical to this is consulting with our cardiology colleagues and making sure that we're identifying heart related issues that are resulting from hormone excess sooner than later because interventions on the earlier side can really make a significant impact on quality of life and associated comorbidities and mortality. Brittany Harvey: Thank you for reviewing those key points for both carcinoid syndrome and carcinoid heart disease symptom management. So then the next set of recommendations. Dr. Del Rivero, what are the key highlights for symptom management of functioning pancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: Yes, it's very important to recognize the symptoms related to hormone excess due to pancreas neuroendocrine tumors. Up to 10% of pancreas neuroendocrine tumors may produce different hormones. Among those hormones can be insulin, gastrin, glucagon, somatostatin. So it's important to know and understand that based on what a neuroendocrine tumor is, they may produce different types of hormones. The importance of these guidelines is to also recognize some of these symptoms and how to address that, because it's not necessarily in these tumor types besides the management of metastatic disease, and know the different options that we recommend for metastatic disease from the systemic therapy, such as chemotherapy or targeted therapies or PRRT. It's important to recognize the symptoms because based on the symptoms we may recommend a different approach. That's something that is important to acknowledge and recognize. Moreover, in certain functional pancreas neuroendocrine tumors, as Dr. Perez mentioned, is a multidisciplinary approach. And it's important to also discuss these different cases with your endocrinologist. You may need to have an experienced endocrinologist to manage, for example, the excess of insulin. And also discuss your cases with a surgeon and interventional radiologist because some of these approaches can certainly improve the symptoms related to hormone excess. I understand that sometimes medical oncologists in the communities may not have access to the multidisciplinary approach or have the different teams that can manage these tumors, and that's the reason why with these guidelines we wanted to establish the understanding of different symptoms associated with the hormone excess to these neuroendocrine tumors as well as how to manage this. For example, in the case of insulinoma, I think for the medical oncologist it is important to know that the everolimus is an option to be used for these tumors, not only to manage tumor progressions related to this tumor type at the same time, because everolimus as a side effect causes hyperglycemia, that can also improve some of the symptoms related to the excess of insulin besides the somatostatin agonist. I think these recommendations will allow the medical oncologist to recognize the symptoms and based on what the symptoms cause, then you can have a different approach that could be added to the systemic therapies options as well. Brittany Harvey: Yes, beyond systemic therapy, it's important to be recognizing symptoms to provide an individualized approach for every single patient. So then, following that overview of symptom management for functioning pancreatic neuroendocrine tumors, Dr. Perez, what is recommended regarding palliative interventions for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, great question. So I think what's unique to neuroendocrine tumors is that the palliative approach really mirrors what we would be doing for symptom management. Some of these patients are living a very long time with carcinoid related symptoms. And so the approach that we take for the carcinoid symptom control is going to mirror the palliative piece of it. I think for those who develop a burden of disease related symptoms, I think it mirrors what we do across the board for all cancer-related complications. And so I think what we attempted to highlight here and included one of our colleagues who focuses specifically on the field of palliative care and neuroendocrine tumors, was to never really lose sight of what we've been doing to care for symptom management throughout the patient's journey and to always rereview the etiology of the symptoms, ensure that we don't focus solely on carcinoid-related issues, but also the symptom management that we would apply to all patients with cancer-related burden symptoms. Brittany Harvey: Definitely. I think that's a helpful approach to consider when thinking about how to manage these palliative interventions as well. So then Dr. Del Rivero, what should clinicians know as they implement these symptom management recommendations? Dr. Jaydira Del Rivero: Yes, thank you so much for that question. As we have discussed in the last 10 or 15 minutes, we have discussed the different approaches on the management of gastroenteropancreatic neuroendocrine tumors. Clinicians, I think it's important to know that neuroendocrine tumors is a quite complex disease because we're not only addressing the management of tumor growth, but we're also addressing the management of the symptoms related to hormone excess and the complexity associated with that. When medical oncologists or clinicians implement these recommendations it's to understand what symptoms these tumors may cause related to the hormone excess but at the same time, how do we approach those symptoms? As Dr. Perez said that I think is very important is to recognize the different types of diarrhea. It doesn't mean that if the patient has worsening diarrhea, it doesn't mean that this is related to disease progression. So it's important to recognize so that way you can address that, because the type of diarrheas can be related because of the lanreotide or somatostatin agonist, it could be because of the prior surgery. I think it's important to recognize those in order to address the symptom. And the same with the gastroenteropancreatic neuroendocrine tumors. It's important to know what hormones they produce because there are different measurements that may be added to the systemic management of these tumors. I think that there are two aspects here, and that's the reason why these guidelines were implemented in the sense that not only we're going to manage disease progression of these tumors, or how do we manage the metastatic disease of these tumors, but at the same time, how do we manage the symptoms related to the hormone excess and the different complications. Moreover, I think, as we discussed earlier, we need to manage these tumors in a multidisciplinary approach. And something very important is not like one size fits all, because the treatment recommendations, it will depend on different characteristics in terms of the tumor presentations. And hormone excess is one of the important aspects to recognize so that way we can implement these recommendations that will definitely help the quality of life of these patients. Brittany Harvey: Absolutely. And using these guidelines in concert with the systemic therapy guidelines is key. And then beyond this impact for clinicians that Dr. Del Rivero has just outlined, Dr. Perez, what does this new guideline mean for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, I think that's an important highlight of this guideline. It really gives patients a voice. I think it recognizes the fact that these symptoms can go unmanaged or mismanaged or just missed, and patients commonly will come in feeling very frustrated and feeling very ill. And I think it will provide them a means to open up a conversation with their providers and say, “Hey, this is what I'm experiencing. Let's talk about what's available. How does this apply to me?” And I think that can be very empowering. I think it's really hard nowadays with so many sources and resources online and patients are really left wondering what are the bullet points that they should be bringing to their clinician appointments? And I think that these guidelines provide them a good framework for those discussions. Brittany Harvey: Yes, bringing these discussion points for patients is very important to be able to have those resources. And we have some patient resources and information available on the website for this guideline and we can link that in the show notes for listeners. So then you've both touched on the importance of this guideline for improving quality of life and we continue to see advancements in this field. So Dr. Del Rivera, what are the outstanding questions regarding symptom management and tumor control for gastroenteropancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: I have to say whenever somebody asks me that question, the word that I will say is I feel hopeful, because more than 10 years ago we didn't have that many options for gastroenteropancreatic neuroendocrine tumors. And it has been in the last decade or so that there has been more developments in the management of these tumors as well as the understanding of the symptoms related to these tumors. But that said, yes, we do need more therapies for gastroenteropancreatic neuroendocrine tumors. Of the treatment options that we have, we all know in the field that even though we have disease control by using the different options for the systemic management of gastroenteropancreatic neuroendocrine tumors, we need options where we can achieve an objective response, especially for these tumor types. But there is a significant volume of disease and we see a lot of these patients with gastroenteropancreatic neuroendocrine tumors. And now where the field is going is to make some of these therapies more effective, to develop more therapies as well. For example, immunotherapies, a different type of immunotherapy understand the tumor immune microenvironment of these tumors in order to develop therapies as well. From the antibody drug conjugates, I think that's a new way to also address or treat these tumor types, understanding about the different markers found on these tumors that way they can be addressed in different ways. Now with the development of new therapies, I think that's something that can help us as well not only have disease control and as well as having an objective response, but having a better objective response can certainly also help with the symptoms related to hormone excess too. In terms of other therapies, I think some of the issues that we encounter are like the refractory carcinoid diarrhea and how do we manage this. We do have therapies that can help us control the diarrhea in the refractory settings, such as telotristat. Telotristat is one of the newer medications that can help us control the refractory diarrhea. But that said, despite this, that we still encounter situations where it's sometimes difficult to control. I think in those situations it will be good to understand more about the biology of these tumors as well and how we manage. If there is a different time or how do we implement these options. I think there is so much to learn. But that said, I feel we're in hopeful times. We're understanding more about these tumors so that way we can help us develop better therapies not only to have control of the tumor growth as well having control of the symptoms. And it's the same with the pancreas neuroendocrine tumors in the metastatic setting. Sometimes it may be difficult to control this hormone excess. But understanding these and having therapies that can achieve more of an objective response, I think that will definitely help us more and manage these patients. But one aspect I want to mention, and Dr. Perez also mentioned as well, the fact that we have these guidelines that help us understand about the different symptoms related to hormone excess and how to address it, I think is very important because having symptoms related to hormone excess can be detrimental to the quality of life on patients with neuroendocrine tumors that may necessarily be related to disease progression and having this information is so important. And I'm hopeful for the different therapies. There's different clinical trials ongoing for neuroendocrine tumors and especially in the field of PRRT. And a lot of more information will come with the different alpha-PRRT and combination therapy. So more information to come in the next couple of years. So this is, in my opinion, hopeful times for this field. Brittany Harvey: It's great to hear that you're hopeful for all the developments in this field and we'll look forward to the development and discovery of new therapies and further research and then, hopefully incorporate those updates into guidelines in the future. So I want to thank you both so much for your work to develop these guidelines and thank you for your time today. Dr. Del Rivero and Dr. Perez. Dr. Jaydira Del Rivero: Thank you so much for having us. Dr. Kim Perez: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

At the American Association for Cancer Research's annual meeting in Chicago, Saranne brings a fresh and heartfelt “pajama party” edition to Beating Cancer Daily, joined by patient advocate and former NBC correspondent Kristen Dahlgren. Both cancer survivors, Saranne and Kristen, reflect on the power of community, milestones on their journeys, and the groundswell of scientific momentum in cancer research, with a special focus on immunology and cancer vaccines. Amid friendship and laughter, they highlight the coalition-building among scientists, lawmakers, and advocates working to accelerate real hope for those facing cancer today. Their candid conversation covers the emotional challenges of survivorship anniversaries, the impact of patient voices in research, and the inspiring stories of others, including long-term Stage IV survivors and advocacy trailblazers.Kristen Dahlgren is a passionate cancer survivor, patient advocate, and former NBC and Today Show correspondent whose life took an unexpected turn after her diagnosis. Now, at her fifth cancer-free anniversary, Kristen is deeply involved with the Cancer Vaccine Coalition, bringing together leading scientists to fast-track cancer vaccine research and connect patient communities with cutting-edge hope. Her experience on both sides—media and advocacy—makes her a respected voice in the conversation for better cures, less toxic treatments, and inclusivity in scientific progress. "My life has changed so dramatically; I was included in this incredible panel and just so happy to be a voice at this moment in time about the hope of cancer research and what we can do to make sure that everybody knows about that hope." ~Kristen DahlgrenToday on Beating Cancer Daily:·     Camaraderie among survivors and advocates at the American Association for Cancer Research meeting is a source of strength and hope.·     Kristen celebrates her five-year cancer-free milestone, emphasizing that survivorship anniversaries bring both gratitude and anxiety.·     The Cancer Vaccine Coalition unites leading doctors and patients worldwide to accelerate the development and accessibility of cancer vaccines.·     Stories like a 12-year Stage IV pancreatic cancer survivor who inspired others, including Alex Trebek, with her public letter highlight the power of advocacy.·     Artificial intelligence is growing in advancing cancer research, improving diagnosis, treatment, and drug discovery.·     Bringing patients' voices directly into scientific and policy discussions is essential, elevating the patient experience in shaping priorities.·     A new documentary, spearheaded by Kristen and supported by patient communities, aims to demystify research breakthroughs and share behind-the-scenes stories.·     All listeners—patients, survivors, caregivers, and loved ones—are invited to connect with the Cancer Vaccine Coalition and join the movement for hope and curesResources Mentioned: AACR (American Association for Cancer Research) Stand Up To Cancer MD Anderson Cancer Center Stanford University (Dr. George Sledge)Guest Contact Information: Kristen Dahlgren: Cancer Vaccine Coalition https://cancervaccinecoalition.org Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Dr. Michael Bauer, Medical Director at Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about the dangers of mixing alcohol and medications, a new study published in the Cancer Research journal suggests that early prostate cancer diagnoses can be made via a mere urine test, how artificial intelligence has been used in the hospital, the […]

Dr. Michael Bauer, Medical Director at Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about the dangers of mixing alcohol and medications, a new study published in the Cancer Research journal suggests that early prostate cancer diagnoses can be made via a mere urine test, how artificial intelligence has been used in the hospital, the […]

A recently published study by the National Cancer Institute (NCI) discovers a link between physical activity and cancer risk after gathering data from wrist sensors, which could help lead to major advances in cancer research. Alaina Shreves, predoctoral fellow at NCI's Division of Cancer Epidemiology and Genetics Metabolic Epidemiology Branch, said the findings come from accelerometer-measured physical activity, which associated low-intensity exercise with up to a 26 percent decreased risk of certain cancers. Shreves highlighted the importance of wrist sensor data in cancer prevention. She also shared her excitement about a new project involving wearable technologies to determine how walking patterns impact cancer development.

Recorded May 4, 2025   May the Fourth Be With You!!!!   In this Star Wars-themed episode, Anna and I go over the final 2 games of the Caps' first round series against the Montreal Canadiens. We also give a brief, non-specific preview of their next round series against the Carolina Hurricanes.   Sorry we're not being more specific, but, muchlike Coach Carbery we're keeping things close to the vest....much like Han Solo who may or may not have fired first.....   Follow the lead of Captain Alex Ovechkin and donate to the V Foundation for Cancer Research: https://donate.v.org/campaign/667859/donate   #ALLCAPS #JenayaTalksCaps #SportsOTHP #LockedOnCapitals #TheOfficialCapsChirpPodcast #SucramsCapitalsOffTheirChainPodcast #ThatsDCHockey          

Among the recipients of the Israel Prize this year is Prof. Yinon Ben Neriah of the Faculty of Medicine at the Hebrew University of Jerusalem, who was recognized for his groundbreaking research in cancer. A distinguished physician, immunologist, and leading cancer researcher, Ben-Neriah's pioneering work has significantly advanced understanding of the biological mechanisms linking chronic inflammation and cancer. Notably, his research identified key processes by which inflammation facilitates cancer development, leading to the creation of novel therapeutic strategies. He spoke to KAN reporter Naomi Segal. (Photo: Bruno Charbit)See omnystudio.com/listener for privacy information.

- Green Tea and Cognitive Benefits (0:10) - Critique of Pharmaceuticals and Big Pharma (2:39) - Green Tea and Brain Health (4:31) - Speed Cubing and Cognitive Training (10:47) - Green Tea and Cancer Prevention (15:59) - Green Tea and Heavy Metal Detoxification (24:45) - L-Theanine and Anxiety Relief (30:04) - Catechins and Polyphenols in Green Tea (36:21) - Green Tea Extracts and Supplements (39:14) - Green Tea and Cancer Therapy (50:57) - Colloidal Silver and Its Benefits (1:11:38) - Silver Nanoparticles and Cancer Research (1:23:02) - Historical and Metaphysical Significance of Metals (1:26:08) - Economic and Political Implications of Metals (1:27:53) - Challenges and Opportunities in Health and Science (1:30:08) - Personal Reflections and Future Plans (1:37:17) - Final Thoughts and Gratitude (1:41:15) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month's American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury's editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury's editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech's therapy. BioCentury's editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year's event. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/655751#biotech #biopharma #pharma #lifescience #AAN #AACR00:01 - Sponsor Message: RemeGen Co.01:02 - Myasthenia Gravis at AAN08:31 - RemeGen's Telitacicept18:03 - AACR: Targets and TrendsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Broadcast from KSQD, Santa Cruz on 04-24-2025: Dr. Dawn issues an alert about hair growth vitamins containing high doses of biotin that can interfere with important medical tests, explaining how biotin supplementation can cause false readings for thyroid function, troponin, parathyroid hormone, sex hormones, vitamin D, testosterone, PSA, and ferritin tests. Responding to an email about non-stick cookware safety, she examines various ceramic-based technologies claiming to be non-toxic, noting concerns about Teflon alternatives like Thermalon and ScanPan, and recommending cast iron as the safest option, particularly for households with pregnant women. A caller inquires about plant-based diets after hearing a radiation oncologist's claim that all animal products are harmful. Dr. Dawn advocates for a balanced approach rather than extreme positions, suggesting practical strategies for increasing vegetable consumption without laborious food preparation. She discusses counterintuitive findings in cancer research where advanced age can actually reduce cancer risk, explaining how aging cells produce a protein called NUPR1 that makes them iron-deficient and less able to regenerate, potentially offering insights for new therapeutic approaches. A caller asks about Dr. Gundry's claims regarding lectins in foods like almonds and peas, with Dr. Dawn explaining that while lectins are plant defense mechanisms that can be toxic in high amounts, moderate consumption is generally safe because the liver builds additional enzymes to process these compounds and this improves general detoxification. Dr. Dawn clarifies misconceptions about soy products, explaining that fermented options like tempeh have fewer anti-nutrients than raw soybeans (edamame). Tofu while not fermented, undergoes processing that reduces anti-nutrient properties by approximately 90%.

Today's Headlines: The State Department is getting a major overhaul, with Secretary Marco Rubio slashing overseas posts and U.S.-based staff by 15%, calling the agency bloated and politically biased. Meanwhile, the Pentagon will soon require women in combat roles to meet the same physical standards as men under a new "sex-neutral" fitness test. Over at HHS, Secretary RFK Jr. is compiling a national autism registry using private medical records, aiming to prove the condition's cause by September. At Harvard, groundbreaking cancer research has stalled because ICE is detaining the scientist who wrote the analysis software—she's now fighting deportation to Russia. Student loan borrowers in default could see their wages garnished starting in May, ending a pandemic-era pause. And Tesla reported a 71% drop in profits, partly due to Elon Musk's political baggage—but its carbon credit sales are booming. Resources/Articles mentioned in this episode: NY Times: Marco Rubio Shares Plans for Overhaul of State Department  NY Times: Female Soldiers Will Have to Pass ‘Sex-Neutral' Physical Test, U.S. Army Says The New Republic: RFK Jr. Set to Launch Disease Registry Tracking Autistic People  NBC News: New images could change cancer diagnostics, but ICE detained the Harvard scientist who analyzes them AP News: Student loans in default to be referred to debt collection, Education Department says WSJ: Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role Morning Announcements is produced by Sami Sage alongside Bridget Schwartz and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

(2:40) - Cancer-on-a-chip technology advances our understanding of how cancer operatesThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about the role of field programmable gate arrays (FPGAs) in the medical world! Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

Tuesday, April 8th, 2025Today, stocks take another dive as the Trump regime plays fast and loose with tariffs; the en banc panel for the DC Circuit Court of Appeals has reinstated Cathy Harris and Gwynne Wilcox to their jobs at the NLRB and MSRP; the North Carolina Supreme Court has temporarily blocked a lower court ruling requiring 65,000 people to cure their ballots; NIH researchers have made a cancer breakthrough but layoffs are delaying it; a second unvaccinated child has died of measles and RFK Jr uses it as an opportunity for a photo op; the Trump administration is planning on spending $45M on immigrant detention; Trump is planning a giant North Korean style military parade on his birthday; and the 4th Circuit Court of Appeals REFUSED to pause an order forcing the Trump admin to return Maryland father Kilmar Abrego Garcia back to the U.S. before midnight tonight; and Allison and Dana deliver your Good News.Thank You, Helix Sleep20% Off Sitewide when you go to HelixSleep.com/dailybeans.Thank You, IQBAR20% off all IQBAR products. Text dailybeans to 64000. Message and data rates may apply. See terms for details. Guest: Bobby Kogan@bbkogan - BlueSkyBobby Kogan - Center for American ProgressStories:Supreme Court delays midnight deadline for Trump administration to fix mistaken deportation of Maryland man | ABC NewsStock Market Volatility Hits 5-Year High As Wall Street Grapples With ‘Manmade' Tariff Problem | ForbesBessent flew to Florida to lobby Trump on tariff message - POLITICON.C. Supreme Court halts decision requiring verification of 65,000 votes in tight judicial race | NBC NewsNIH scientists have a cancer breakthrough. Layoffs are delaying it. | The Washington PostAppeals court halts Trump independent agency firings, spurring Supreme Court battle | The HillRFK Jr. visits Texas after second child dies of measles amid outbreak | The Washington PostTrump Administration Aims to Spend $45 Billion to Expand Immigrant Detention - The New York TimesTrump planning military parade through DC for 79th birthday | The HillGood Trouble:The Heritage Foundation DOGE Survey Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen. Check out other MSW Media podcastsShows - MSW MediaCleanup On Aisle 45 podSubscribe for free to MuellerSheWrote on SubstackThe BreakdownFollow AG and Dana on Social MediaAllison Gill Substack|Muellershewrote, BlueSky|@muellershewrote, Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWroteDana GoldbergBlueSky|@dgcomedy, IG|dgcomedy, facebook|dgcomedy, danagoldberg.com, Twitter|@DGComedyShare your Good News or Good Trouble:dailybeanspod.com/goodFrom The Good News50501 South Dakota hosts ‘Hands Off' protests around the state | Dakota News NowBlue.Wing.Things to do in Case of COUP | YouTubeReminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen.Share your Good News or Good Trouble:https://www.dailybeanspod.com/good/ Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, BlueSky|@muellershewrote , Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWrote,Dana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts

In this episode of "Impact Theory with Tom Bilyeu," join Tom and his co-host Drew as they break into a whirlwind of current events, political intrigue, and innovations in technology. The dynamic duo dives headfirst into a plethora of topical discussions, starting with the transformative shift in perceptions toward Chinese innovation and its impact on global research, particularly in cancer treatments. They dissect the complicated narrative surrounding public reactions to government actions, showcasing how those on the ground often bear the brunt of political gamesmanship. The conversation takes an electrifying turn as Tom and Drew explore the new heights of space endeavors, applauding the Spirit of SpaceX for rescuing astronauts amidst political hurdles. Amidst this, they scrutinize the controversial chatter around Tesla's market moves and the implications for average investors. Get ready for an engaging session that promises to educate and provoke thought on these pressing issues. SHOWNOTES 00:00 Intro and Setting the Scene 00:48 Chinese Innovation and Cancer Research 06:12 Public Reactions and Political Missteps 11:54 SpaceX's Stellar Rescue Mission 17:30 Tesla Stock and Political Perceptions 21:00 Doxxing and Market Influence 23:58 Tariffs and China's Economic Edge 30:41 Housing Market Bubbles 40:25 Manufacturing and AI Impacts 49:28 Robotics and Advances in Technology 53:17 Satellites and Wildfire Detection CHECK OUT OUR SPONSORS Range Rover: Range Rover: Explore the Range Rover Sport at https://rangerover.com/us/sport Audible: Sign up for a free 30 day trial at https://audible.com/IMPACTTHEORY  Vital Proteins: Get 20% off by going to https://www.vitalproteins.com and entering promo code IMPACT at check out Thrive Market: ​​Go to https:thrivemarket.com/impact for 30% off your first order, plus a FREE $60 gift! Tax Network: Stop looking over your shoulder and put your IRS troubles behind you. Call 1-800-958-1000 or visit https://tnusa.com/impact ITU: Ready to breakthrough your biggest business bottleneck? Apply to work with me 1:1 - https://impacttheory.co/SCALE American Alternative Assets: If you're ready to explore gold as part of your investment strategy, call 1-888-615-8047 or go to https://TomGetsGold.com Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at https://mintmobile.com/impact.  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details.  ********************************************************************** What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER SCALING a business: see if you qualify here. Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here. ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** Join me live on my Twitch stream. I'm live daily from 6:30 to 8:30 am PT at www.twitch.tv/tombilyeu ********************************************************************** LISTEN TO IMPACT THEORY AD FREE + BONUS EPISODES on APPLE PODCASTS: apple.co/impacttheory ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Learn more about your ad choices. Visit megaphone.fm/adchoices